Wen S, Kuri-Morales P, Hu F, Nag A, Tachmazidou I, Deevi S
Nat Genet. 2025; 57(3):572-582.
PMID: 39948438
PMC: 11906367.
DOI: 10.1038/s41588-025-02085-6.
Wang W, Fu F, Li Y, Li S, Yuan M, Wang T
Reprod Sci. 2025; 32(3):716-727.
PMID: 39934615
PMC: 11870962.
DOI: 10.1007/s43032-025-01801-1.
Kittke V, Zhao C, Lam D, Harrer P, Krezel W, Schormair B
Sci Rep. 2024; 14(1):28986.
PMID: 39578497
PMC: 11584712.
DOI: 10.1038/s41598-024-80266-9.
Liu Y, Li Q, Song L, Gong C, Tang S, Budinich K
Cancer Discov. 2024; 14(8):1522-1546.
PMID: 38655899
PMC: 11294821.
DOI: 10.1158/2159-8290.CD-23-0876.
Ge G, Zhang P, Sui P, Chen S, Yang H, Guo Y
J Clin Invest. 2023; 134(1).
PMID: 37917239
PMC: 10760961.
DOI: 10.1172/JCI163964.
Differential transcriptional control of hematopoiesis in congenital and cyclic neutropenia patients harboring mutations.
Zeidler A, Borbaran-Bravo N, Dannenmann B, Ritter M, Nasri M, Klimiankou M
Haematologica. 2023; 109(5):1393-1402.
PMID: 37855057
PMC: 11063862.
DOI: 10.3324/haematol.2023.284033.
The NCOR-HDAC3 co-repressive complex modulates the leukemogenic potential of the transcription factor ERG.
Kugler E, Madiwale S, Yong D, Thoms J, Birger Y, Sykes D
Nat Commun. 2023; 14(1):5871.
PMID: 37735473
PMC: 10514085.
DOI: 10.1038/s41467-023-41067-2.
Meis1 establishes the pre-hemogenic endothelial state prior to Runx1 expression.
Coulombe P, Cole G, Fentiman A, Parker J, Yung E, Bilenky M
Nat Commun. 2023; 14(1):4537.
PMID: 37500618
PMC: 10374625.
DOI: 10.1038/s41467-023-40283-0.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill C, Birdwell C, Davis J, Das K, Boettcher S
Blood Cancer J. 2023; 13(1):53.
PMID: 37055414
PMC: 10102188.
DOI: 10.1038/s41408-023-00826-6.
De Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy.
Ding J, Li Y, Larochelle A
Cells. 2023; 12(2).
PMID: 36672255
PMC: 9857267.
DOI: 10.3390/cells12020321.
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill C, Sasaki K, Birdwell C
Leukemia. 2022; 36(11):2729-2733.
PMID: 36151141
PMC: 9613474.
DOI: 10.1038/s41375-022-01707-w.
Triple-negative Thrombocythemia and Subsequent Acute Lymphoblastic Leukemia with Additional Somatic Mutations.
Tsuboi Y, Sakamoto T, Makishima K, Suehara Y, Hattori K, Kurita N
Intern Med. 2022; 62(10):1527-1530.
PMID: 36104197
PMC: 10258111.
DOI: 10.2169/internalmedicine.0269-22.
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
Tanaka A, Nakano T, Nomura M, Yamazaki H, Bewersdorf J, Mulet-Lazaro R
Blood. 2022; 140(8):875-888.
PMID: 35709354
PMC: 9412007.
DOI: 10.1182/blood.2021015325.
Elucidating the importance and regulation of key enhancers for human MEIS1 expression.
Xiang P, Yang X, Escano L, Dhillon I, Schneider E, Clemans-Gibbon J
Leukemia. 2022; 36(8):1980-1989.
PMID: 35624144
PMC: 9343249.
DOI: 10.1038/s41375-022-01602-4.
Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice.
Muranyi A, Ammer T, Kechter A, Rawat V, Sinha A, Gonzalez-Menendez I
Blood Adv. 2022; 7(3):351-364.
PMID: 35468619
PMC: 9898611.
DOI: 10.1182/bloodadvances.2022007015.
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W, Boettcher S, Daver N, Mill C, Sasaki K, Birdwell C
Blood Cancer J. 2022; 12(1):5.
PMID: 35017466
PMC: 8752621.
DOI: 10.1038/s41408-021-00603-3.
Discrete regulatory modules instruct hematopoietic lineage commitment and differentiation.
Georgolopoulos G, Psatha N, Iwata M, Nishida A, Som T, Yiangou M
Nat Commun. 2021; 12(1):6790.
PMID: 34815405
PMC: 8611072.
DOI: 10.1038/s41467-021-27159-x.
Interplay between FLI-1 and the LDB1 complex in murine erythroleukemia cells and during megakaryopoiesis.
Giraud G, Kolovos P, Boltsis I, van Staalduinen J, Guyot B, Weiss-Gayet M
iScience. 2021; 24(3):102210.
PMID: 33733070
PMC: 7940982.
DOI: 10.1016/j.isci.2021.102210.
MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.
VanOpstall C, Perike S, Brechka H, Gillard M, Lamperis S, Zhu B
Elife. 2020; 9.
PMID: 32553107
PMC: 7371429.
DOI: 10.7554/eLife.53600.
Development of Small Molecule MEIS Inhibitors that modulate HSC activity.
Turan R, Albayrak E, Uslu M, Siyah P, Alyazici L, Kalkan B
Sci Rep. 2020; 10(1):7994.
PMID: 32409701
PMC: 7224207.
DOI: 10.1038/s41598-020-64888-3.
